No article text was recorded for this version.
antibody-dependent enhancement
Version 1 of 122 papers35 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
- Blog: Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
- Blog: P173 Investigating varicella-zoster virus-specific T cells through the lenses of HIV
- Blog: Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine
- Blog: In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG
- Blog: Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
- Blog: The Role of CD4+CD8+ T Cells in HIV Infection With Tuberculosis
- Blog: Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates
- Blog: Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses
- Blog: Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
- Blog: Modeles mathematiques dynamiques pour la medecine personnalisee
- Blog: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- Blog: Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study
- Blog: Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
- Blog: Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation
- Blog: Insidious Insights: Implications of viral vector engineering for pathogen enhancement
- Blog: Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
- Blog: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- Blog: Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
- Blog: COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis
- Blog: Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
- Blog: An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens
History & citation
Current · Permanent link
- Immune Activation as a Driver of Viral Susceptibility merged into this direction (82% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_antibody_dependent_enhancement_ac33b970,
title = {antibody-dependent enhancement},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/antibody-dependent-enhancement/rdr_ac33b970e87243608f35e4c36686cc95},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_antibody_dependent_enhancement_ac33b970_v1,
title = {antibody-dependent enhancement},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/antibody-dependent-enhancement/rdr_ac33b970e87243608f35e4c36686cc95/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}